Spirit Magazine - April 2014 - (Page 26)
certain beauty in his behavior.
Maybe it's because I saw myself
in him. My life's obsession is the
harp. It propels me out of bed
each morning. I played full time
for more than 20 years. About
15 years ago, an injury forced
me to stop. Although devastated
by this turn of events, I was introduced to new ways of sharing my
love for the instrument. I became
Important Information for Patients about PATADAY®
(olopatadine hydrochloride ophthalmic solution) 0.2%
This summary contains risk and safety information for
patients about PATADAY® Solution. This summary does
not include all information about PATADAY® Solution and
is not meant to take the place of talking to your healthcare
provider about your medical condition or treatment. Please
see the full Prescribing Information for complete product
information available at www.Pataday.com. Read the
Prescribing Information that comes with PATADAY® Solution
before you start using it and each time you get a refill.
There may be new information. If you have questions about
PATADAY® Solution, talk to your doctor or pharmacist.
INDICATIONS AND USAGE
PATADAY® Solution is indicated for the treatment of ocular
itching associated with allergic conjunctivitis.
DOSAGE AND ADMINISTRATION
The recommended dose is one drop in each affected
eye once a day.
DOSAGE FORMS AND STRENGTHS
Ophthalmic solution 0.2%: each ml contains 2.22 mg of
olopatadine hydrochloride.
CONTRAINDICATIONS
None.
WARNINGS AND PRECAUTIONS
For topical ocular use only.
Not for injection or oral use.
Contamination of Tip and Solution
As with any eye drop, to prevent contaminating the dropper tip
and solution, care should be taken not to touch the eyelids
or surrounding areas with the dropper tip of the bottle.
Keep bottle tightly closed when not in use.
Contact Lens Use
Patients should be advised not to wear a contact lens
if their eye is red.
PATADAY® (olopatadine hydrochloride ophthalmic
solution) 0.2% should not be used to treat contact
lens related irritation.
The preservative in PATADAY® Solution, benzalkonium
chloride, may be absorbed by soft contact lenses. Patients
who wear soft contact lenses and whose eyes are not red,
should be instructed to wait at least ten minutes after
instilling PATADAY® (olopatadine hydrochloride ophthalmic
solution) 0.2% before they insert their contact lenses.
ADVERSE REACTIONS
Symptoms similar to cold syndrome and pharyngitis were
reported at an incidence of approximately 10%.
The following adverse experiences have been reported
in 5% or less of patients:
Ocular: blurred vision, burning or stinging, conjunctivitis, dry
eye, foreign body sensation, hyperemia, hypersensitivity, keratitis,
lid edema, pain and ocular pruritus.
Non-ocular: asthenia, back pain, flu syndrome, headache,
increased cough, infection, nausea, rhinitis, sinusitis and
taste perversion.
Some of these events were similar to the underlying
disease being studied.
a private instructor and opened
one of the few harp stores in
America-Harps Etc.-in Walnut
Creek, California. My obsession
helped guide me to a new life. So,
you see, sometimes an obsession
is a good thing.
-J E S S I C A S I EG E L
WA L N U T C R E E K , C A L I FO R N I A
A good thing, indeed. Talk about
striking a chord, Jessica.
USE IN SPECIFIC POPULATIONS
Pregnancy
Teratogenic effects: Pregnancy Category C
Olopatadine was found not to be teratogenic in rats
and rabbits. However, rats treated at 600 mg/kg/day,
or 150,000 times the maximum recommended ocular
human dose (MROHD) and rabbits treated at 400 mg/kg/day,
or approximately 100,000 times the MROHD, during
organogenesis showed a decrease in live fetuses. In addition,
rats treated with 600 mg/kg/day of olopatadine during
organogenesis showed a decrease in fetal weight. Further,
rats treated with 600 mg/kg/day of olopatadine during late
gestation through the lactation period showed a decrease
in neonatal survival and body weight. There are, however,
no adequate and well-controlled studies in pregnant
women. Because animal studies are not always
predictive of human responses, this drug should be used
in pregnant women only if the potential benefit to the
mother justifies the potential risk to the embryo or fetus.
Nursing Mothers
Olopatadine has been identified in the milk of nursing
rats following oral administration. It is not known whether
topical ocular administration could result in sufficient
systemic absorption to produce detectable quantities in the
human breast milk. Nevertheless, caution should be exercised
when PATADAY® (olopatadine hydrochloride ophthalmic
solution) 0.2% is administered to a nursing mother.
Pediatric Use
Safety and effectiveness in pediatric patients below the age
of 2 years have not been established.
Geriatric Use
No overall differences in safety and effectiveness have been
observed between elderly and younger patients.
NONCLINICAL TOXICOLOGY
Carcinogenesis, Mutagenesis, Impairment of Fertility
Olopatadine administered orally was not carcinogenic
in mice and rats in doses up to 500 mg/kg/day and
200 mg/kg/day, respectively. Based on a 40 μL drop size
and a 50 kg person, these doses were approximately
150,000 and 50,000 times higher than the MROHD. No
mutagenic potential was observed when olopatadine was
tested in an in vitro bacterial reverse mutation (Ames) test,
an in vitro mammalian chromosome aberration assay or an
in vivo mouse micronucleus test. Olopatadine administered
to male and female rats at oral doses of approximately
100,000 times MROHD level resulted in a slight decrease
in the fertility index and reduced implantation rate; no
effects on reproductive function were observed at doses
of approximately 15,000 times the MROHD level.
OPERATION COOKIE
Our love for Southwest (and
Spirit magazine) was proclaimed
loudly this holiday season. For
years, we have sent cookies
as gifts. The inspiration for this
year's gifts was discovered while
on a flight to a friend's wedding.
We used six recipes from your
September 2013 cookie issue, with
overwhelming success. Total
cookies baked: 1,018. Total boxes
sent: 42. Total states represented:
12. The response was extremely
positive. Thank you for entertaining us, in flight and on the ground.
-LORI & TORREY BIEVENOUR
INDIANAPOLIS
Sweet! One question: Can we get on
the list for next year?
UNCLE WALLY
This is a very belated note to tell
you how much I enjoyed your
profile of Wally Amos ["Are You
Famous Amos?," September 2013].
I got hooked on Uncle Noname
cookies at one point in my life-
they were always in the vending
machine, and I was always
working late-and I remember
the packaging making reference
to Wally not being able to use his
famous name. I always wondered
about the backstory and what
became of him. Your story gave
me this information and so much
more. I really enjoyed learning
about his life, both the highs and
the lows, and I appreciate that you
neither glorified nor demonized
him. After reading your story,
I feel like I know the man, yet I
also understand what his kids
went through and how they
perceive him now.
- D AV E K L I N E
S A C R A M E N T O, C A L I FO R N I A
We're glad you liked the story, Dave.
Rx only
Reference: 1. IMS Health, IMS National Prescription Audit, August 2010 to
October 2013, USC 61500 OPHTH ANTI-ALLERGY.
‡
This information is an estimate derived from the use of information under
license from the following IMS Health information service: National Prescription
Audit for the period 2004-2013. IMS expressly reserves all rights, including
rights of copying, distribution and republication.
© 2014 Novartis
1/14
PAT14001JAD
CORRECTION
The March Rapid Rewards Freedom Story
reported that Taylor Hicks will perform at
Caesars Palace. The actual venue is Paris
Las Vegas. We regret this error.
http://www.Pataday.com
http://www.Pataday.com
Table of Contents for the Digital Edition of Spirit Magazine - April 2014
Spirit Magazine - April 2014
Contents
Gary’s Greeting
Gary’s Greeting en Español
Star of the Month
Freedom Story
From the Editor
Your Words
Your Pictures
Media Center
Eat Drink Sleep
Rustle up ribs
shake up a summer sipper
Wise Guide
Take better snaps
Make finance a family affair
Numbers
Make time for sweets
Learn from the Bard
Business
Zen out with Russell Simmons
Store more on your iPhone
Chasing Beautiful Questions
Connection Error
Get out of your social comfort zone
Your Adventure In Santa Fe
Destination Texas
Calendar
Fun!
Spotlight
Community Outreach
Products & Services
Flight Service
Terminal Maps
Information
Rapid Rewards and A+ Rewards Partners
Route Map
The "If" List
Touch base with Tracy Morgan
Spirit Magazine - April 2014
https://www.nxtbook.com/nxtbooks/pace/southwest_201412
https://www.nxtbook.com/nxtbooks/pace/southwest_201411
https://www.nxtbook.com/nxtbooks/pace/southwest_201410
https://www.nxtbook.com/nxtbooks/pace/southwest_201409
https://www.nxtbook.com/nxtbooks/pace/spirit_201408
https://www.nxtbook.com/nxtbooks/pace/spirit_201407
https://www.nxtbook.com/nxtbooks/pace/spirit_201406
https://www.nxtbook.com/nxtbooks/pace/spirit_201405
https://www.nxtbook.com/nxtbooks/pace/spirit_201404
https://www.nxtbook.com/nxtbooks/pace/spirit_201403
https://www.nxtbook.com/nxtbooks/pace/spirit_201402
https://www.nxtbook.com/nxtbooks/pace/spirit_201401
https://www.nxtbook.com/nxtbooks/pace/spirit_201312
https://www.nxtbook.com/nxtbooks/pace/spirit_201311
https://www.nxtbook.com/nxtbooks/pace/spirit_201310
https://www.nxtbook.com/nxtbooks/pace/spirit_201309
https://www.nxtbook.com/nxtbooks/pace/spirit_201308
https://www.nxtbook.com/nxtbooks/pace/spirit_201307
https://www.nxtbook.com/nxtbooks/pace/spirit_201306
https://www.nxtbook.com/nxtbooks/pace/spirit_201305
https://www.nxtbook.com/nxtbooks/pace/spirit_201304
https://www.nxtbookmedia.com